BioNexus Gene Lab Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BioNexus Gene Lab Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.42M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $9.51M | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $9.77M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $10.93M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $13.36M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $11.39M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $127.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $212.3K | Mar 31, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $1.29M | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $1.33M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.26M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.27M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.72M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $55.9K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $28.8K | Mar 31, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.98M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($1.60M) | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | ($2.63M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($356.0K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $751.6K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.09M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($246.5K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $26.5K | Mar 31, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.97M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($1.57M) | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | ($2.59M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($291.2K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.06M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.27M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($275.7K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $59.9K | Mar 31, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.7K | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $47.5K | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $55.0K | Apr 15, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.84M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($2.09M) | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | ($1.82M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $551.8K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $9.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $552.7K | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($217.3K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($274.1K) | Mar 31, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.0K | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $227.0K | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $149.4K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $3.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $421.6K | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $12.8K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($39.6K) | Mar 31, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.25M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $10.43M | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $11.40M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $8.74M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $9.57M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.12M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $1.23M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.65M | Mar 31, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $637.9K | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $2.11M | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $1.74M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.08M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.39M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.45M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $108.9K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $130.3K | Mar 31, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.61M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $8.32M | Apr 14, 2026 |
| FY2025 | Dec 31, 2023 | $9.66M | Apr 14, 2026 |
| FY2024 | Dec 31, 2022 | $6.67M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $7.18M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | $6.66M | Mar 31, 2023 |
| FY2021 | Jan 1, 2020 | $1.12M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $1.12M | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | $1.52M | Mar 30, 2021 |
| FY2019 | Jan 1, 2018 | $94.6K | Mar 31, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.43M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($3.44M) | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | ($1.84M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.16M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.51M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $760.8K | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($333.3K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($86.8K) | Mar 31, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.49M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $2.89M | Apr 14, 2026 |
| FY2021 | Dec 31, 2021 | $2.12M | Apr 6, 2022 |
| FY2021 | Dec 31, 2020 | $2.79M | Apr 6, 2022 |
| FY2021 | Dec 31, 2019 | $859.1K | Apr 6, 2022 |
| FY2020 | Dec 31, 2018 | $1.26M | Mar 30, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.42M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | 1.80M | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | 17.67M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 14.48M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 171.22M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 171.22M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | 102.73M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 74.63M | Mar 31, 2020 |